Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 4/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | TSPO | P30536 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1678985 | 0.85 | MMP3 (0.54) | ESR1ESR2ARMMP3NEK1 | |
| SCHEMBL9543269 | 0.84 | ESR2 (0.45) | ESR1ESR2TYRCYP19A1AR | |
| SCHEMBL28667436 | 0.83 | TYR (0.58) | ESR1ESR2TYRMMP3 | |
| SCHEMBL29700948 | 0.79 | IDO1 (0.48) | FFAR1TSPODRD3FFAR4NEK1 | |
| SCHEMBL548158 | 0.79 | IDO1 (0.48) | FFAR1TSPODRD3FFAR4NEK1 | |
| Hydrochloric Acid SCHEMBL17204528 | 0.78 | IDO1 (0.50) | FFAR1TSPODRD3FFAR4NEK1 | |
| SCHEMBL24136215 | 0.76 | FFAR1 (0.45) | CYP19A1FFAR1TSPODRD3FFAR4 | |
| SCHEMBL12069868 | 0.76 | FFAR1 (0.36) | ESR1ESR2FFAR1TSPODRD3 | |
| SCHEMBL444029 | 0.76 | CYP2A6 (0.49) | FFAR1TSPODRD3FFAR4 | |
| SCHEMBL22904093 | 0.76 | ESR2 (0.49) | ESR1ESR2TYRCYP19A1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112028825-B | Tyrosine kinase inhibitor and pharmaceutical composition containing same | 广东众生睿创生物科技有限公司 | 2025-03-14 | — | — | CN | disclosed |
| EP-3293177-B1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GUANGDONG RAYNOVENT BIOTECH CO LTD (CN) | 2024-11-27 | — | — | EP | disclosed |
| CN-112028825-A | Tyrosine kinase inhibitor and pharmaceutical composition containing same | 广东众生睿创生物科技有限公司 | 2020-12-04 | — | — | CN | disclosed |
| CN-107683279-B | Tyrosine kinase inhibitor and pharmaceutical composition containing same | 广东众生睿创生物科技有限公司 | 2020-11-03 | — | — | CN | disclosed |
| US-10654808-B2 | Tyrosine kinase inhibitor and pharmaceutical composition comprising same | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2020-05-19 | — | — | US | disclosed |
| US-20190119217-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-04-25 | — | — | US | disclosed |
| EP-3293177-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-14 | — | — | EP | disclosed |
| CN-1656088-A | Substituted chroman derivatives having cytochrome P450RAI inhibitory activity | ALLERGAN INC (US) | 2005-08-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119217-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ABL1, LCK, ERBB2 | ESR1 2044/4885ESR2 2686/4885TYR 106/4885 |
| US-10654808-B2 | Tyrosine kinase inhibitor and pharmaceutical composition comprising same | ABL1, LCK, ERBB2 | ESR1 2044/4885ESR2 2686/4885TYR 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.